---
layout: post
title: "Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice-Extended-Release/Long-Acting Opioid Analgesic Postmarketing Requirement"
date: 2026-02-04 21:51:33 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-06787
original_published: 2025-04-21 00:00:00 +0000
significance: 8.00
---

# Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice-Extended-Release/Long-Acting Opioid Analgesic Postmarketing Requirement

**Published:** February 04, 2026 21:51 UTC
**Source:** Federal Register
**Original Published:** April 21, 2025 00:00 UTC
**Document Number:** 2025-06787

## Summary

The Food and Drug Administration (FDA) is announcing an amendment to the notice of joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee. This meeting was announced in the Federal Register of December 9, 2024. The amendment is being made to reflect changes in the DATES, ADDRESSES, and Procedure portions of the document. There are no other changes.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/04/21/2025-06787/joint-meeting-of-the-drug-safety-and-risk-management-advisory-committee-and-the-anesthetic-and)
- API: https://www.federalregister.gov/api/v1/documents/2025-06787

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
